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Abstract – Marek’s disease virus (MDV) is an oncogenic alphaherpesvirus that is highly conta-
gious in poultry. Recombinant RB-1B (rRB-1B) reconstituted from an infectious genome cloned
as a bacterial artificial chromosome (BAC) is unable to spread horizontally, quite in contrast to
parental RB-1B. This finding suggests the presence of one or several mutations in cloned relative to
parental viral DNA. Sequence analyses of the pRB-1B bacmid identified a one-nucleotide insertion
in the UL13 orthologous gene that causes a frame-shift mutation and thereby results in a theo-
retical truncated UL13 protein (176 aa vs. 513 aa in parental RB-1B). UL13 genes are conserved
among alphaherpesviruses and encode protein kinases. Using two-step “en passant” mutagenesis,
we restored the UL13 ORF in pRB-1B. After transfection of UL13-positive pRB-1B DNA (pRB-
1B*UL13), the resulting, repaired virus did not exhibit a diﬀerence in cell-to cell spread (measured
by plaque sizes) and in UL13 transcripts in culture compared to parental rRB-1B virus. Although
89% of the chickens inoculated with rRB-1B*UL13 virus developed tumors in visceral organs,
none of the contact birds did. MDV antigens were clearly expressed in the feather tips of rRB-1B
infected chickens, suggesting that the UL13 gene mutation did not alter virus tropism of the feather
follicle. The results indicate that the correction in UL13 gene alone is not suﬃcient to restore in vivo
spreading capabilities of the rRB-1B virus, and that other region(s) of pRB-1B might be involved
in the loss-of-function phenotype. This finding also shows for the first time that a full UL13 ORF is
dispensable for MDV tumor formation and feather follicle tropism.
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1. INTRODUCTION
Marek’s disease virus (MDV) is a highly
contagious avian herpesvirus. MDV is the
etiological agent of Marek’s disease in
chickens, a multi-faceted disease, most
widely recognized by the induction of
a malignant T-cell lymphoma. The virus
spreads very eﬃciently from infected to
uninfected chickens by direct or indirect
contact. It is believed that free infectious
virus is shed from the feather follicle ep-
ithelium [1, 4]. In all other cell types – in
cell culture, or in vivo – MDV is strongly
cell-associated and does not release de-
tectable quantities of free infectious viri-
ons. The molecular mechanism involved in
the release of free virus from feather folli-
cle cells remains unknown and to date no
viral genes have been implicated in this bi-
ological property.
The MDV genome is approximately
185 kbp in size and encodes at least
103 proteins [32]. Several MDV genomes
have been cloned as bacterial artificial
chromosomes, including an avirulent strain
(584Ap80C) (yielding the bacmid BAC20)
and the highly virulent strain RB-1B
(yielding the bacmid pRB-1B) [21, 26].
The viruses derived from these bacmids
are able to replicate in cell culture. Re-
combinant virus from pRB-1B is highly
oncogenic in chickens, but is unable to
spread from infected to naïve chickens
[10, 11]. Horizontal spread, thus far, is
the only property lacking in rRB-1B to
make it a full model to study MDV bi-
ology. Despite this shortcoming, pRB-1B
and its derivatives are great tools to deter-
mine the molecular determinants involved
in MDV horizontal dissemination in birds
by individual, consequential or concomi-
tant repair of genes that are found to be
diﬀerent from authentic, wild-type MDV
[17, 32].
The UL13 gene is conserved in all mem-
bers of the Herpesviridae. The MDV UL13
gene consists of a 1539-bp ORF encoding a
513 amino acids (aa) protein with an appar-
ent molecular weight of 60 kDa [24]. MDV
UL13 presents a high homology with the
orthologs of HSV-1 and VZV which en-
code the unique-long protein kinases [24].
Analysis of the MDV UL13 aa sequence
reveals that UL13 MDV is also a protein
kinase [24].
The HSV-1 UL13 protein (pUL13) is a
tegument protein. It can phosphorylate it-
self and at least five other viral proteins:
VP22, ICP22, ICP0, the unique-short pro-
tein kinase pUS3, and gE [5, 6, 12, 19, 20,
22]. pUL13 can also phosphorylate cellular
factors such as the eukaryotic elongation
factor ∂EF-1 [13]. The biological func-
tions of pUL13 are still unclear. Studies
on mutant viruses indicate that UL13 is
dispensable for replication in cell culture
[5]. The suppression of the UL13 kinase
activity is associated to the formation of
smaller plaques [30]. The examination of
these HSV-1 UL13 mutants in mice has
never been described. The VZV ORF47
protein (pUL13 ortholog) also autophos-
phorylates and phosphorylates the major
immediate-early transactivator IE62 pro-
tein, IE63 protein, gE, as well as the ORF9
and ORF32 products [16, 23, 29]. ORF47,
while not necessary in cultured cells, is
required for skin and T-cell infection in
SCID-hu mice [9, 18].
In this study, we report on the identifica-
tion of a single mutation in the UL13 gene
in the pRB-1B bacmid. We took advantage
of this mutation to investigate the role of
the UL13 gene in pathogenesis in vivo. We
also investigate whether repairing this gene
could restore the horizontal in vivo dissem-
ination of pRB-1B-derived virus.
2. MATERIALS AND METHODS
2.1. Cells and bacmids
Chicken embryonic skin cells (CESC)
were prepared and cultivated as previ-
ously described [7] from 12-day chicken
embryos (LD1 Brown Leghorn chicken
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strain) [25]. The pRB-1B bacmid, herein
referred to as ‘pRB-1B’, consists of the
genome of the highly virulent RB-1B
strain cloned into a bacterial artificial chro-
mosome (BAC). This bacmid was a kind
gift from V. Nair (IAH Compton, UK) [21].
2.2. Antibodies to MDV antigens
The mouse monoclonal antibodies
(Mabs) F19 (IgG1) and H18 (IgG1)
against VP5, the major capsid protein,
were used1 [8]. K11 Mab (IgG1) against
MDV-1 gB was obtained by immunizing a
Balb/c mouse with baculovirus-expressed
gB, and following a procedure described
earlier [7]. The K11 Mab was found to
react with both MDV and the serologically
related herpesvirus of turkeys (HVT).
MAb E21 (IgG1) directed against ICP4
was obtained using the same protocol.
2.3. Sequencing of nucleotide regions
in pRB-1B
The entire UL13 and UL48 ORF of
pRB-1B bacmid were sequenced as well
as the regions corresponding to the cy-
toplasmic domain (CD) of gB, gD, gE
and gM encoded by UL27, US6, US8 and
UL10 respectively (MWG-biotech, Ebers-
berg, Germany). These sequences were
compared to the ones of the Md5 com-
plete genome (GenBank accession number
AF243438) with MegAlign sofware ver-
sion 3.08 from DNASTAR Inc. The nu-
cleotide positions of the regions sequenced
are the following ones: UL13 (36339 to
37880), UL48 (109813 to 111096), CD
gB (61055 to 61405), CD gD (161002 to
161076), CD gE (163643 to 163882) and
CD gM (34251 to 34490).
2.4. Generation of the pRB-1B*UL13
bacmid by “en passant”
mutagenesis
The pRB-1B*UL13 bacmid, corre-
sponding to the pRB-1B bacmid with a
1 Kut E., Rasschaert D., unpublished data.
deletion of a single T nucleotide in the
UL13 gene, was generated by using “en
passant” mutagenesis, exactly as previ-
ously described by Tischer et al. [31]. The
UL13 gene from pRB-1B*UL13 was se-
quenced in its entirety on both strands
(MWG-biotech) using UL12-13, UL14-13,
and UL13rseq primers (Tab. I).
2.5. Generation of the pRB-1B*UL13-
derived virus
pRB-1B*UL13 (3 µg) was transfected
into 50% confluent CESC grown in 60-mm
dishes by using the calcium phosphate pre-
cipitation method [14]. Six days later, cell
monolayers showing viral plaques were
harvested and amplified on fresh CESC.
2.6. DNA analyses
Virus DNA was purified from approxi-
mately 0.5–1 × 107 infected CESC grown
in a 100-mm dish as described previously
[27] and was amplified by PCR using
UL12-13 and UL14-13 primers located in
UL13 flanking sequences. The PCR prod-
uct was purified with micropure EZ col-
umn (Millipore, Bedford, MA, USA), con-
centrated on Microcon YM30 (Millipore)
and directly sequenced on both strands
(MWG-biotech) using UL12-13, UL14-13,
and UL13rseq primers (Tab. I).
2.7. Transcription examination
of the UL13 region by RT-PCR
Infected CESC (0.5–1 × 107) grown
in a 100-mm dish were trypsinized and
washed in Phosphate Buﬀered Saline so-
lution (PBS). The pellet of cells was im-
mediately resuspended in RNAble solution
(Eurobio, Les Ulis, France). Total RNA ex-
traction was performed according to the
manufacturer’s instructions. RNA prepara-
tions were treated with RNAse-free RQ1
DNAse (Promega, Madison, WI, USA)
and quantified by measuring the optical
density at 260 nm. One microgram of
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Table I. Primers for mutagenesis and sequencing.
Table II. Primers used for RT-PCR analysis of MDV mRNA.
total RNA was reverse transcribed using
oligo(dT) primers and Moloney murine
leukemia virus reverse transcriptase ac-
cording to the manufacturer’s recommen-
dations (Promega). Five percent of the
synthesized cDNA was then subjected to
PCR amplification with 1 µM of each
primer (total volume of reaction mixture,
25 µL). The primers used for the RT-PCR
are described in Table II. Twenty micro-
liters of each RT-PCR mixture was elec-
trophoresed on a 0.8% or 1.5% agarose
gel and visualized by ethidium bromide
staining.
2.8. Measurement of virus plaque size
Cells (1.5 × 106) were infected with
200 PFU of recombinant RB1B (rRB-1B)
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or rRB-1B*UL13 viruses. Four days post-
infection, the cells were fixed with 4%
paraformaldehyde (Sigma, St. Louis, MO,
USA) and stained with a cocktail of three
of the Mabs described above (F19 anti-
VP5, K11 anti-gB, and E21 anti-ICP4;
each diluted at 1:1000) followed by a
goat anti-mouse Alexa 488 (Invitrogen,
Carlsbad, CA, USA). Plaques were ob-
served with a 4× Achroplan lens (NA 0.1;
Zeiss, Göttingen, Germany) mounted on an
Axiovert 200 M inverted epi-fluorescence
microscope (Zeiss). Measurements were
performed on images captured from 100
plaques through a CCD Axiocam MRm
camera (Zeiss) using the Axiovision soft-
ware (Zeiss). Statistical analysis (ANOVA)
was performed with the SAS software ver-
sion 8.
2.9. In vivo experiments
Sixty-five one-week-old specific-
pathogen-free B13/B13 white leghorn
chicks were randomly allocated to 4 dif-
ferent groups: nine birds were inoculated
with rRB-1B and housed with ten naïve
contact birds (group 1); nine birds were
inoculated with rRB-1B*UL13 and housed
with ten contact birds (group 2); nine birds
were injected with parental, wild-type
RB-1B virus and housed with ten contact
birds (group 3); eight negative control
birds (group 4). Chicks were injected
intramuscularly in the pectoral region with
0.2 mL of a cell suspension containing
1 000 plaque-forming units (pfu) of each
virus stock. For pRB-1B-derived viruses,
virus stocks consisted of infected CESC
grown in culture; for the RB-1B virus
strain, the inoculum consisted of a suspen-
sion of peripheral blood leukocytes from
previously infected chickens. The injected
chicks were raised with the naive chicks
(contacts). Birds were observed twice a
day for clinical disease. Birds presenting
severe clinical signs were killed. All
surviving birds were killed on day 162.
All birds were examined for gross patho-
logical lesions. Statistical analyses were
performed using the Pearson’s chi-square
test and the Mann-Whitney U Test.
2.10. Detection of MDV in feather tips
Feather tips from actively growing
feathers were collected from the pec-
toral zone of birds injected with pRB-1B-
derived virus. The biopsies were 5–10 mm
long and 2–4 mm wide. For indirect flu-
orescence analysis (IFA), feather samples
were embedded in Shandon Cryomatrix
(Thermo electron corporation, Waltham,
MA, USA), immediately frozen in dry
ice, and stored at –80 ◦C until use. Sec-
tions (8-µm thick and perpendicular to the
axis of the feather) were performed with
a cryostat at –20 ◦C (Leica Microsystems,
Wetzlar, Germany), collected on Super-
frost Plus glass slides, dried, fixed, and
permeabilized in ethanol/acetone (1:1) at
–20 ◦C. The feather tip sections were
stained with the anti-ICP4 E21 Mab, fol-
lowed by a goat anti-mouse antibody con-
jugated to Alexa Fluor 594 (Invitrogen),
and with the anti-VP5 H18 MAb directly
coupled to Oregon Green with the Flu-
oReporter kit (Invitrogen). Sections were
inspected with the Axiovert 200 M in-
verted epi-fluorescence microscope (Zeiss)
described above with the Apotome system.
For immunohistochemistry, feather sam-
ples were immediately placed into histo-
cassettes and fixed in 3% paraformalde-
hyde for 48 h. Samples were processed
for dehydration and paraﬃn embedding in
a TP1020 automat (Leica Microsystems)
during 20 h. Embedded samples were kept
at –20 ◦C until sectioning on an AS325
Shandon microtome (Thermo electron cor-
poration). Sections (6-µm thick) were col-
lected on Superfrost slides, dried at 37 ◦C
for 2 days, and stained with the anti-VP5
F19 MAb after removal of the paraﬃn
and rehydration. Endogenous peroxydase
activity was blocked by incubating the sec-
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tions in methanol containing 1% H2O2. To
avoid non-specific binding of antibodies,
the sections were blocked by incubation
with normal goat serum in a 1:5 dilu-
tion in phosphate-buﬀered saline (PBS) for
20 min. The secondary goat anti-mouse an-
tibody coupled to horseradish peroxidase
was diluted at 1:1000 in ChemMate anti-
body diluant (Dako) and revealed by the
peroxidase DAB system (Dako). Sections
were inspected with a B×41 right micro-
scope (Olympus, Rungis, France) and pic-
tures were taken with a DP50 color digital
camera (Olympus).
3. RESULTS
3.1. Identification of a single mutation
in the UL13 gene in the pRB-1B
BAC clone
In order to determine why this virus
does not spread from infected to naïve
chickens, we determined the nucleotide
sequence of selected genes or region of
genes that might be involved in the spread-
ing. The complete UL48 ORF and the
sequences encoding the cytoplasmic do-
mains of gB, gD, gE and gM were identical
to the ones of the Md5 sequence. A single
point mutation, an additional T nucleotide
at position 37368 of the Md5 sequence,
was found in the UL13 homologous open
reading frame. The pRB-1B UL13 nu-
cleotide sequence was submitted to Gen-
Bank and assigned the accession number
EF110558. This additional nucleotide in
UL13 ORF is responsible for a frame-shift
and the introduction of a premature stop
codon. Consequently, the predicted UL13
ORF is shortened from 1541 to 528 bp
(Fig. 1A) and the theoretical protein prod-
uct from 513 to 176 amino acids (Fig. 1B).
The shortened pRB-1B pUL13 is devoid
of the serine/threonine protein kinase ac-
tive sites (involved in phosphate transfer)
predicted at amino acid positions 264-276
in pUL13 according to ScanProsite2. We
2 www.expasy.org/prosite.
speculated that this important modification
of the unique-long serine/threonine protein
kinase may be associated with a loss-of-
function of the protein or a complete ab-
sence of protein expression.
3.2. Construction and analysis
of a UL13-repaired pRB-1B virus
To investigate the function of UL13 for
horizontal spread of MDV in vivo, a re-
paired pRB-1B bacmid with a restored
UL13 ORF (termed pRB-1B*UL13) was
constructed. For this, the additional T
in the coding sequence of the pRB-
1B genome was removed using two-
step “en passant” mutagenesis. In a first
step, a linear PCR fragment encoding
kanR, an I-SceI site and 58 bp of the
UL13 gene covering the region to repair
was obtained using 5FUL13Wtpepk and
3RUL13Wtpepk primers (Tab. I). The PCR
fragment was electroporated into EL250
containing the pRB-1B bacmid target to
allow homologous recombination. Indi-
vidual kanamycin and chloramphenicol
double-resistant colonies harboring BAC
clones were selected. One of these colonies
was chosen to perform the second muta-
genesis step. Electrocompetent cells were
prepared from this colony and transformed
with the pBAD-I-SceI plasmid containing
the I-sceI gene under the control of an ara-
binose inducible promoter. This second re-
combination step conducted to the elimina-
tion of the KanR marker. The transformants
were selected on LB agar plates contain-
ing ampicillin, chloramphenicol and 1% of
arabinose.
One of the positive colonies (CmR
KanS) from this final mutagenesis was se-
lected for further analysis. First, the en-
tire UL13 ORF from the bacmid isolated
from E. coli was verified by sequencing.
Then, the BAC DNA was transfected into
primary CESC, amplified for the produc-
tion of a master stock of cell-associated
virus, and frozen in liquid nitrogen. The
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Figure 1. Generation and characterization of pRB-1B*UL13, a pRB-1B derived BAC harboring a
full-length UL13 ORF. A. Schematic representation of the MDV genome in the UL13 region and
part of the sequence for pRB-1B UL13 and for the repaired pRB-1B*UL13. The three underlined
nucleotides correspond to the premature stop codon in UL13 ORF of pRB-1B due to the presence
of an extra T. In pRB-1B*UL13, the additional T (position 37,668 of UL13 in Md5 sequence) has
been removed. B. Schematic illustration of the UL13 protein with its functional domains and the
theoretical amino acid sequences of pUL13 for rRB-1B and rRB-1B*UL13 between aa145 and
aa176. The functional domains were determined using ScanProsite. C. Sequence around nucleotide
514 in UL13 gene from rRB-1B and rRB-1B*UL13. Viral DNA of each virus was obtained from
infected CESC and approximately 1800 bp was amplified by PCR with UL12-13 and UL13-14
primers (Tab. I) and was sequenced. The sequence of each virus was identical, with the exception
of the desired T deletion in rRB-1B*UL13. D. UL13 mRNA expression. Total RNA were purified
from CESC infected with rRB-1B, rRB-1B*UL13 or parental RB-1B viruses, 5 days post-infection.
Mock represents non infected CESC. RT-PCR were performed for UL13 with three couples of
primers, UL13f943-962 and UL13rseq (couple UL13-1), UL13seq and UL13rseq (couple UL13-2)
and 5’fUL13BglII and 3’rUL13EcoRI (couple UL13-3) (Tab. I). The expression of US2 or UL49
encoding the major tegument protein VP22 was also done as controls. The pRB-1B viruses derived
from bacmids are lacking US2 since the mini-F cassette was introduced in the US2 locus for the
bacmid construction. This gene allows distinguishing the pRB-1B derived viruses from the RB-1B
strain. We showed that the region UL13 is transcribed for the two pRB-1B derived viruses as well
as for the RB-1B strain.
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UL13 gene from the rRB-1B*UL13 viral
genomic DNA was analyzed by PCR using
UL12-13 and UL14-13 primers (Tab. I).
As expected, this PCR fragment was sim-
ilar in size to the PCR fragment obtained
from pRB-1B viral DNA (not shown). The
sequence of the 1 830 bp PCR product
was verified and found to be identical to
the Md5 and the repaired BAC sequences
(Fig. 1C). We concluded that the muta-
tion was stably introduced into the genome
of the derived virus. The expression of
UL13 mRNA was evaluated by RT-PCR
with three couples of primers from total
RNA extracted from infected CESC. We
showed that UL13 mRNA are expressed
for the two pRB-1B derived viruses as well
as the RB-1B strain (Fig. 1D). No protein
analysis of the pUL13 by Western blot or
immunofluorescence could be performed
since all our eﬀorts to develop antibodies
against pUL13 remained unsuccessful.
3.3. Cell-to-cell spread of the pRB-
1B*UL13-derived virus in cell
culture
To study the cell-to-cell spread of both
viruses in vitro, plaque size measurements
were performed on CESC. The cells were
coseeded with 200 pfu of each virus,
fixed four days post-infection, and ana-
lyzed by fluorescence microscopy. Mean
plaque areas measured for both viruses
were 1.908 ± 0.054 and 1.820 ± 0.059 ×
105 µm2 for rRB-1B and rRB-1B*UL13,
respectively, showing no significant diﬀer-
ence in cell-to-cell spreading (p > 0.05;
ANOVA after square root transformation).
3.4. Pathogenesis and horizontal
dissemination of rRB-1B*UL13
compared to rRB-1B and RB-1B
strain
Three groups of nine 1-week-old
B13/B13 chickens were infected with
103 PFU of one of the three viruses:
rRB-1B, rRB-1B*UL13, or the authen-
tic, parental RB-1B strain. One group
of eight negative control chickens was
also included. Each infected group was
raised with ten 1-week-old naive chickens
(contacts). The four groups of chickens
were monitored for clinical signs and
gross pathological lesions. All the birds
injected with lymphocytes infected with
the highly virulent RB-1B died within 16
days. rRB-1B and rRB-1B*UL13 viruses
induced visceral tumors in 100% and 89%
of the birds injected, respectively, with
a mean time to disease onset of 42 and
36 days (Fig. 2A). The diﬀerence in the
percentage of birds developing tumors due
to the absence or presence of the UL13
gene was not statistically significant (Pear-
son’s chi-square test). The diﬀerence in
mean time to the onset of the disease was
also not statistically significant (Mann-
Witney U test). The tumors from both
groups of chickens were predominantly
observed in kidneys, liver, and in the
muscle. These results showed that rRB-1B
and rRB-1B*UL13 virus do not diﬀer
in terms of pathogenesis in inoculated
birds. Moreover, we could conclusively
demonstrate that a full UL13 ORF is not
essential for MDV pathogenesis and does
not influence disease progression in the
pRB-1B background.
All (100%) chickens in the rRB-1B and
in the rRB-1B*UL13 contact groups sur-
vived during the 162 days of the experi-
ment, whereas 100% of the RB-1B strain
contacts developed tumors and died within
the first 55 days, with a mean survival time
of 48 days (Fig. 2B). In the rRB-1B and
rRB1B*UL13 contact groups, none of the
surviving chickens developed clinical dis-
ease or showed evidence of gross lesions.
Therefore, we concluded that the restora-
tion of the UL13 ORF was not suﬃcient to
rescue the horizontal spread of MDV in the
pRB-1B background.
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Figure 2. In vivo characterization of the pRB-1B*UL13 derived virus. A. Cumulative incidence of
MD in birds infected with rRB-1B*UL13 and rRB-1B viruses. Virus stocks (103 pfu) were inoc-
ulated by intra-muscular route into groups (n = 9) of 1-week-old specific pathogen-free B13/B13
chickens. The cumulative incidence of the disease in the first 69-day period, time to death, is ex-
pressed as a percentage. B. Percentage of survival of naïve birds in contact with birds injected with
rRB-1B*UL13, rRB-1B, or parental RB-1B viruses. Each injected group was raised with a naïve
group (n = 10) of one-week old specific-pathogen-free B13/B13 chickens.
3.5. MDV antigens in feather tips
of chickens infected with pRB-1B-
derived virus compared to
the RB-1B strain
In order to determine whether the lack
of dissemination of the rRB-1B-derived
virus is due to an absence of feather
tropism, the feathers of birds injected with
rRB-1B or the RB-1B strain were an-
alyzed by immunofluorescence and im-
munochemistry. In birds injected with
pRB-1B-derived virus as well as in birds
injected with the RB-1B strain (Fig. 3A),
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MDV lytic replication was detected in
feather follicle epithelial cells by staining
with a monoclonal antibody to VP5, the
major capsid protein. Double immunoflu-
orescence staining also clearly showed the
colocalisation of VP5 and ICP4, a pro-
tein with immediate-early kinetics, to the
epithelial layer (Fig. 3B). The VP5 anti-
gen was found by immunohistochemistry
in the nuclei of cells which appeared to be
of epithelial lineage, although no markers
for epithelial or lymphoid cells could be
used in this experiment. Both viruses ap-
peared to infect the same cells in the same
tissue region and the infection was con-
sistently restricted to the uppermost zone
of the skin epithelium in contact with the
feather quill. These results show that the
pRB-1B-derived virus is not impaired in
feather tropism and that the UL13 gene is
not dispensable for skin tropism in vivo.
4. DISCUSSION
The identification of a mutation in the
UL13 gene of pRB-1B and the construc-
tion of a repaired BAC clone, named pRB-
1B*UL13, indicated that the MDV UL13
homologous gene is not essential for some
of the MDV properties in vitro and in
vivo. Experiments with two recombinant
MDV reconstituted from infectious DNA
demonstrated that a full-length UL13 ORF
is dispensable for in vitro infectivity. This
was in agreement with the results obtained
for other alphaherpesviruses. Indeed, the
UL13 ortholog was found to be non es-
sential for the replication of PRV, HSV-1,
and VZV in cultured cells [5, 9, 15]. In
this study, we also report that no diﬀer-
ence can be observed between rRB-1B and
rRB-1B*UL13 with respect to plaque size.
This was in accordance with the results de-
scribed for VZV where no apparent diﬀer-
ences in plaque morphology were observed
between a mutant lacking ORF47 protein
expression and the parental P-Oka virus in
a human melanoma cell line [9]. Curiously
for PRV and HSV-1, UL13 mutants exhibit
slight plaque size reductions [15, 30]. A
possible explanation is that pUL13 func-
tion involved in cell-to-cell spread in vitro
is compensated by a viral or a cellular pro-
tein expressed in the cell types used to
grow VZV and MDV.
The results reported here also show that
a full-length UL13 ORF is not essential
for oncogenicity of MDV. This was the
first time such an observation was made
on an oncogenic herpesvirus. In terms of
cellular tropism, this result also shows that
the rRB-1B devoid of a full UL13 ORF
is capable of spreading to T cells in vivo.
This result was surprising since the VZV
ORF47 is required for eﬃcient replication
in T lymphocytes in vitro and for growth
in human fetal lymphocytes implanted in
mice with severe combined immunodefi-
ciency (SCID) [3, 28]. This obvious dis-
crepancy suggests that there is a diﬀerence
between VZV and MDV with respect to the
viral determinants involved in the T-cell
tropism of the two viruses in their target
species. Alternatively, the blockade in the
cytolytic process into T-cells (due to the
Figure 3. Detection of MDV antigens in the
feather tips of chickens after infection with the
rRB-1B-derived viruses and the RB-1B strain.
A. Immunofluorescence of VP5 and ICP4 anti-
gens. Each image corresponds to a projection
of eleven 0.275-µm thick slices VP5 (light
grey/green), localized in the nucleus which is
stained with Hoechst 33342 (dark grey/blue).
ICP4 (grey/red) is localized in the nuclei and
cytoplasm of infected cells. Bars represent
20 µm. B. Immunochemistry of VP5 antigen
(MCP). MCP antigen was detected in the nu-
clei of the cells forming the epithelial layer in
contact with the feather shaft. The feather shaft
is not visible on the feather tip of the rRB-
1B-infected chicken. Bars represent 20 µm.
(A color version of this figure is available at
www.edpsciences.org/vetres.)
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lack of pUL13) is common to both viruses
and only aﬀects spreading from T-cells to
skin cells but does not aﬀect the transfor-
mation process.
We were unable to determine whether
the rRB-1B-derived viruses express
pUL13 and/or a pUL13 protein kinase
activity because of the lack of pUL13
antibodies. The absence of pUL13 kinase
activity is predictable owing to the dele-
tion of the conserved DFG (DFS in UL13
MDV) motif, which is present in almost
all kinases and considered necessary for
the transfer of phosphate from ATP to the
substrate. We cannot, however, exclude
that the truncated (176 aa) MDV pUL13
product has another function besides
kinase activity. For instance, such an
alternative function has been identified for
the rOka∆C mutant encoding for a 268-aa
long ORF47 product [2]. It is also possible
that the truncated MDV pUL13 product is
not expressed like for the VZV ROka47
considered as an ORF47 null mutant,
i.e. not expressing a shortened protein
product encoded by ORF47 (165 codons)
in infected cells [9].
In this study we showed that MDV
structural proteins are present in the feather
tips of chickens infected with rRB-1B
demonstrating that pUL13 is not required
for MDV targeting to feathers and repli-
cation in this tissue. However, the cell
types expressing MDV antigens within the
feather follicle remain to be determined.
In the absence of double staining with a
cellular marker, we cannot formally ex-
clude that the cells expressing MDV anti-
gens were infected-T cells. This result also
shows that the presence of late MDV anti-
gens in the feathers might not be associated
with horizontal dissemination of the virus.
One hypothesis is that, although rRB-1B
is present in feather follicles, virus mor-
phogenesis may not be entirely complete,
which in consequence would not allow the
formation of enveloped and fully infec-
tious virions as is the case after infection
with the parental RB-1B strain. This exper-
iment was originally designed to study the
impact of the UL13 gene in MDV trans-
mission in vivo. By successfully construct-
ing a pRB-1B-derived virus harboring a
full-length UL13 ORF, we demonstrated
that the integrity of the UL13 ORF is still
not suﬃcient to restore MDV horizontal
dissemination. Therefore, this phenotype
may be attributable to other mutations else-
where in the pRB-1B sequence.
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